JP2021534160A - 疾患処置のためのリルゾール口腔内崩壊錠の使用 - Google Patents

疾患処置のためのリルゾール口腔内崩壊錠の使用 Download PDF

Info

Publication number
JP2021534160A
JP2021534160A JP2021507740A JP2021507740A JP2021534160A JP 2021534160 A JP2021534160 A JP 2021534160A JP 2021507740 A JP2021507740 A JP 2021507740A JP 2021507740 A JP2021507740 A JP 2021507740A JP 2021534160 A JP2021534160 A JP 2021534160A
Authority
JP
Japan
Prior art keywords
riluzole
administration
cancer
disease
vas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507740A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020037152A5 (https=
JP2021534160A5 (https=
Inventor
ブラディミア・コリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of JP2021534160A publication Critical patent/JP2021534160A/ja
Publication of JPWO2020037152A5 publication Critical patent/JPWO2020037152A5/ja
Publication of JP2021534160A5 publication Critical patent/JP2021534160A5/ja
Priority to JP2023179961A priority Critical patent/JP2024010017A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021507740A 2018-08-16 2019-08-15 疾患処置のためのリルゾール口腔内崩壊錠の使用 Pending JP2021534160A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023179961A JP2024010017A (ja) 2018-08-16 2023-10-19 疾患処置のためのリルゾール口腔内崩壊錠の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862764864P 2018-08-16 2018-08-16
US62/764,864 2018-08-16
PCT/US2019/046709 WO2020037152A1 (en) 2018-08-16 2019-08-15 Use of riluzole oral disintigrating tablets for treating diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023179961A Division JP2024010017A (ja) 2018-08-16 2023-10-19 疾患処置のためのリルゾール口腔内崩壊錠の使用

Publications (3)

Publication Number Publication Date
JP2021534160A true JP2021534160A (ja) 2021-12-09
JPWO2020037152A5 JPWO2020037152A5 (https=) 2022-03-02
JP2021534160A5 JP2021534160A5 (https=) 2022-03-02

Family

ID=69525906

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021507740A Pending JP2021534160A (ja) 2018-08-16 2019-08-15 疾患処置のためのリルゾール口腔内崩壊錠の使用
JP2023179961A Pending JP2024010017A (ja) 2018-08-16 2023-10-19 疾患処置のためのリルゾール口腔内崩壊錠の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023179961A Pending JP2024010017A (ja) 2018-08-16 2023-10-19 疾患処置のためのリルゾール口腔内崩壊錠の使用

Country Status (15)

Country Link
US (1) US20210315865A1 (https=)
EP (1) EP3836922B1 (https=)
JP (2) JP2021534160A (https=)
KR (1) KR20210045423A (https=)
CN (1) CN112584831A (https=)
AU (1) AU2019322889A1 (https=)
BR (1) BR112021002692A2 (https=)
CA (1) CA3109769A1 (https=)
EA (1) EA202190544A1 (https=)
ES (1) ES2987802T3 (https=)
IL (1) IL280657A (https=)
MX (2) MX2021001563A (https=)
PH (1) PH12021550218A1 (https=)
SG (1) SG11202100880VA (https=)
WO (1) WO2020037152A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023531919A (ja) * 2020-06-24 2023-07-26 バイオヘイブン・セラピューティクス・リミテッド 強迫性障害を治療するための組成物及び方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114177153B (zh) * 2021-12-20 2023-04-07 平顶山市第二人民医院 一种利鲁唑口崩片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524622A (ja) * 1999-04-08 2003-08-19 アール．ピー． シェーラー コーポレイション 魚類ゼラチン含有の急速分散型投与形態
JP2017535613A (ja) * 2014-11-21 2017-11-30 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールの舌下製剤
JP2018508525A (ja) * 2015-03-03 2018-03-29 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
MXPA05005528A (es) * 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US9241902B2 (en) * 2003-12-17 2016-01-26 R.P. Scherer Technologies, Llc Chewable soft capsules containing ungelatinized starch
US8778979B2 (en) * 2005-04-05 2014-07-15 Yale University Glutamate agents in the treatment of mental disorders
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
PT2467372T (pt) * 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
US9434704B2 (en) * 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
MX2017006454A (es) * 2014-11-21 2018-03-23 Biohaven Pharm Holding Co Ltd Administracion sublingual de riluzol.
WO2016085998A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
JP2020506231A (ja) * 2017-01-31 2020-02-27 パオロ エル マンフレディ 神経系の障害並びにその症状及び徴候の処置又は予防のため並びに疾患及び細胞の老化並びにその症状及び徴候に対する細胞保護のための化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524622A (ja) * 1999-04-08 2003-08-19 アール．ピー． シェーラー コーポレイション 魚類ゼラチン含有の急速分散型投与形態
JP2017535613A (ja) * 2014-11-21 2017-11-30 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールの舌下製剤
JP2018508525A (ja) * 2015-03-03 2018-03-29 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023531919A (ja) * 2020-06-24 2023-07-26 バイオヘイブン・セラピューティクス・リミテッド 強迫性障害を治療するための組成物及び方法
JP7805969B2 (ja) 2020-06-24 2026-01-26 バイオヘイブン・セラピューティクス・リミテッド 強迫性障害を治療するための組成物及び方法

Also Published As

Publication number Publication date
EP3836922B1 (en) 2024-08-07
IL280657A (en) 2021-03-25
WO2020037152A1 (en) 2020-02-20
JP2024010017A (ja) 2024-01-23
ES2987802T3 (es) 2024-11-18
CN112584831A (zh) 2021-03-30
AU2019322889A1 (en) 2021-03-04
SG11202100880VA (en) 2021-02-25
US20210315865A1 (en) 2021-10-14
MX2021001563A (es) 2021-06-15
PH12021550218A1 (en) 2021-12-06
EA202190544A1 (ru) 2021-06-18
BR112021002692A2 (pt) 2021-05-11
MX2024007642A (es) 2024-07-04
CA3109769A1 (en) 2020-02-20
EP3836922A1 (en) 2021-06-23
KR20210045423A (ko) 2021-04-26
EP3836922C0 (en) 2024-08-07
EP3836922A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
EP3836922B1 (en) Use of riluzole oral disintigrating tablets for treating diseases
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
EP3220891B1 (en) Sublingual formulation of riluzole
US20260014123A1 (en) Use of riluzole oral disintegrating tablets for treating diseases
WO2023186827A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
US20210290651A1 (en) Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
WO2024160392A1 (en) 5-meo-dmt for use in the treatment of postpartum depression
Nehra et al. Olutasidenib: A ray of hope in the treatment of acute myeloid leukaemia
EA046859B1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
Danyeli et al. Ketamine in Psychiatric Disorders
JP2025510915A (ja) 産後うつ病の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
AU2023428136A1 (en) 5-meo-dmt for use in the treatment of postpartum depression
HK1243318B (en) Sublingual formulation of riluzole
HK1243318A1 (en) Sublingual formulation of riluzole

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230620